Medtronic MDT Ratios & Valuation
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 260.7%-0.1pp | 261%+0.1pp | 261.4%+0.3pp | 260.9%-0.5pp | 260.8%-1.1pp | |
| Operating margin | 70.6%+3.8pp | 70.5%+5.6pp | 70.3%+4.7pp | 68.8%+2.2pp | 66.8%-1.9pp | |
| Net margin | 53.5%+1.8pp | 54.2%+5.0pp | 54.1%+4.7pp | 53.4%+4.1pp | 51.8%+3.1pp | |
| EBITDA margin | 104.7%+5.2pp | 105%+7.8pp | 104.2%+6.1pp | 102%+2.4pp | 99.4%-2.7pp | |
| Free cash flow margin | 60.7%-3.7pp | 61.2%-3.8pp | 62.4%-1.4pp | 64.1%+4.3pp | 64.4%+6.3pp | |
| Returns | ||||||
| Return on equity | 38.8%+4.3pp | 38.4%+6.2pp | 37.4%+5.6pp | 36.2%+5.0pp | 34.4%+4.1pp | |
| Return on assets | 20.7%+1.7pp | 20.6%+2.7pp | 20.3%+2.5pp | 19.8%+2.3pp | 19%+1.9pp | |
| Return on invested capital | 27%+2.8pp | 26.9%+4.0pp | 26.3%+3.8pp | 25.5%+3.3pp | 24.3%+2.7pp | |
| Efficiency | ||||||
| Asset turnover | 1.5×+0.1× | 1.5×+0.1× | 1.5×+0.1× | 1.5×+0.1× | 1.5×+0.1× | |
| Inventory turnover | 8.5×+0.2× | 8.4×+0.2× | 8.4×+0.1× | 8.4×+0.1× | 8.3×+0.1× | |
| Liquidity | ||||||
| Current ratio | 9.1×+1.4× | 8.8×+0.9× | 8.2×-0.1× | 7.6×-1.1× | 7.7×-1.3× | |
| Quick ratio | 6.8×+0.9× | 6.6×+0.6× | 6.2×-0.1× | 5.7×-0.8× | 5.8×-0.9× | |
| Cash ratio | 0.5×0.0× | 0.5×+0.1× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 2.4×0.0× | 2.4×+0.2× | 2.4×+0.2× | 2.3×+0.3× | 2.3×+0.3× | |
| Debt-to-assets | 1.3×0.0× | 1.3×+0.1× | 1.3×+0.1× | 1.3×+0.1× | 1.2×+0.1× | |
| Net debt / EBITDA | 11.9×-1.1× | 12.1×-0.9× | 12.2×-0.6× | 12.6×+0.3× | 13×+1.2× | |
| Interest coverage | 34.6×+5.0× | 33.7×+5.1× | 32.6×+3.3× | 30.9×+0.5× | 29.6×-2.9× | |
| Per Share | ||||||
| Book value per share | $151.37+0.7% | $150.20-0.4% | $150.61-0.5% | $150.52-1.1% | $150.29-2.2% | |
| Valuation | ||||||
| Market capitalization | $467.91B+4.9% | $472.07B+6.1% | $456.53B+2.7% | $455.62B+7.7% | $446.21B+2.9% | |
| Enterprise value | $577.41B+4.5% | $581.78B+6.0% | $564.67B+3.3% | $562.87B+7.8% | $552.68B+4.4% | |
| Price / earnings | 99.5×-5.0× | 101×-9.3× | 99.8×-10.9× | 102.3×-4.4× | 104.5×-7.4× | |
| Price / sales | 13.3×-0.2× | 13.7×+0.1× | 13.5×-0.2× | 13.6×+0.5× | 13.5×0.0× | |
| Price / book | 9.6×+0.4× | 9.8×+0.7× | 9.4×+0.4× | 9.4×+1.0× | 9.2×+0.7× | |
| EV / EBITDA | 62.8×-4.6× | 64.2×-4.6× | 64×-4.5× | 66×+1.1× | 67.3×+2.5× | |
| EV / sales | 16.4×-0.3× | 16.9×+0.1× | 16.6×-0.1× | 16.8×+0.7× | 16.7×+0.2× | |
| Free cash flow yield | 18.4%-0.7pp | 18%-1.2pp | 18.6%-0.2pp | 18.8%+0.6pp | 19.1%+1.9pp | |
| Earnings yield | 16.2%+0.9pp | 15.9%+1.4pp | 16.1%+1.6pp | 15.7%+0.6pp | 15.4%+0.9pp | |
| Dividend yield | 12.5%-0.5pp | 12.3%-0.8pp | 12.6%-0.5pp | 12.7%-1.2pp | 13%-0.6pp | |
| PEG ratio | 14.2×-15.2× | 7.8×— | 23.9×— | 27.6×— | 29.4×— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Medtronic's profit margins?
- Medtronic (MDT) runs a 64.9% gross margin and a 17.0% operating margin, with a 13.0% net margin.
- Where do Medtronic's ratios come from?
- Every ratio is computed from Medtronic's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
